RecruitingPhase 1NCT04953910
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- ASTX727(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (22)
- MD Anderson, Houston, Texas, United States
- Erebuni Medical Center, Yerevan, Armenia
- Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders), Yerevan, Armenia
- Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology), Yerevan, Armenia
- National Center of Oncology Named After V.A. Fanarjyan, Yerevan, Armenia
- Complex Oncology Center - Plovdiv - Base II, Plovdiv, Bulgaria
- BIO1, Vilnius, Lithuania
- Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw, Poland
- Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania
- Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania
- Summit Clinical Research s.r.o, Bratislava, Slovakia
- START Barcelona - Hospital HM Nou Delfos, Barcelona, Spain
- Hospital Universitari Dexeus - Grupo Quirónsalud, Barcelona, Spain
- START Rioja - Hospital de San Pedro, La Rioja, Spain
- Hospital Universitari Arnau de Vilanova, Lleida, Spain
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04953910 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute